HOME > TOP STORIES

TOP STORIES

COMMENTARY Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key

February 5, 2026
BUSINESS Trazenta Faces Multiple Patent Challenges Ahead of Anticipated Generic Entry

February 4, 2026
BUSINESS Sawai Cedes to Merck in Januvia Row, Accepts Patent Scope

February 4, 2026
ORGANIZATION FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D

February 3, 2026
BUSINESS AstraZeneca Names Andy Barnett as New Japan President

February 3, 2026
BUSINESS Fuji Says Eylea Biosimilar Patent Risk Cleared under Global Settlement

February 2, 2026
BUSINESS Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit

January 30, 2026
REGULATORY Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs

January 30, 2026
REGULATORY Entyvio, Rexulti, and Lenvima among 15 More Drugs Picked for IRA Price Talks

January 29, 2026
REGULATORY Japan’s Lower House Campaign Begins amid Fragmented Political Set-Up

January 28, 2026
REGULATORY Former LDP Lawmakers Outline Drug Policy Priorities in Comeback Bids

January 28, 2026
BUSINESS Ajinomoto Builds Presence in ADC CDMO Business with Proprietary Technology

January 27, 2026
REGULATORY Japan Panel OKs AbbVie’s Aquipta, Ipsen’s Sohonos, and Novo’s IcoSema for Approval

January 26, 2026
BUSINESS Will Unlisted AGs Rush for June Listing or Be Left on Ice?

January 23, 2026
REGULATORY Japan’s 1st Xolair Biosimilar Likely from Celltrion as JAN Is Assigned

January 23, 2026
REGULATORY DPP Vows to Scrap Off-Year Drug Price Revisions in Election Platform

January 23, 2026
REGULATORY Japan Health Minister Says Early Call on FY2027 Off-Year Revision Improves Predictability

January 22, 2026
REGULATORY PMDA Chief Vows Stronger Support for Drug Discovery, Orphan Designations

January 21, 2026
ORGANIZATION OTC Industry Head Urges Caution on Extra Charges for “OTC-Like” Drugs

January 20, 2026
REGULATORY AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery

January 20, 2026

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…